A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Trial Profile

A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Amphotericin B (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Therapeutic Use
  • Sponsors Matinas BioPharma
  • Most Recent Events

    • 05 Dec 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 05 Dec 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 05 Dec 2017 Planned initiation date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top